Susquehanna Fundamental Investments’s Niagen Bioscience NAGE Stock Holding History

Susquehanna Fundamental Investments’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-43,662	Closed	-$73.4K	–	1133
2022 Q4	$73.4K	Sell	43,662 -12,527	-22%	-$19.9K	﹤0.01%	1131
2022 Q3	$69K	Buy	+56,189	New	+$90.4K	﹤0.01%	1360
2022 Q1	$156K	Buy	63,333 +50,478	+393%	+$138K	﹤0.01%	1404
2021 Q4	$48K	Buy	12,855 +2,086	+19%	+$11.3K	﹤0.01%	1370
2021 Q3	$68K	Buy	+10,769	New	+$88.7K	﹤0.01%	1647

Other funds holding NAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Susquehanna Fundamental Investments's NAGE Position: Q1 2023 in Review

Susquehanna Fundamental Investments sold out of Niagen Bioscience (NAGE) in Q1 2023, closing a stake of 43,662 shares — an estimated $73.4K sold.

Susquehanna Fundamental Investments first reported a position in NAGE in Q3 2021 and held it in 5 quarters. The position peaked at $156K in Q1 2022. 59 funds tracked by Wall St. Rank hold NAGE as of Q1 2023.

Susquehanna Fundamental Investments reported no remaining Niagen Bioscience position as of Q1 2023 after selling out during the quarter.
Susquehanna Fundamental Investments sold 43,662 Niagen Bioscience shares in Q1 2023, an estimated $73.4K.
Susquehanna Fundamental Investments first reported a position in Niagen Bioscience in Q3 2021 and held it in 5 quarters.
Susquehanna Fundamental Investments's Niagen Bioscience position peaked at $156K in Q1 2022.
59 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2023.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2023, filed 16 May 2023.